Juergen Stein

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8884387/publications.pdf

Version: 2024-02-01

254 papers	8,643 citations	43973 48 h-index	49773 87 g-index
289 all docs	289 docs citations	289 times ranked	8784 citing authors

#	Article	IF	Citations
1	Relevance of Biotin Deficiency in Patients with Inflammatory Bowel Disease and Utility of Serum 3 Hydroxyisovaleryl Carnitine as a Practical Everyday Marker. Journal of Clinical Medicine, 2022, 11, 1118.	1.0	9
2	Glycemic control and BMI changes after endoscopic implantation of a duodenojejunal bypass liner compared with laparoscopic Roux-en-Y gastric bypass surgery: a propensity score matching analysis. Surgical Endoscopy and Other Interventional Techniques, 2022, 36, 5979-5985.	1.3	3
3	Letter: the sphingosine 1 phosphate/sphingosine 1 phosphate receptor axisâ€"a unique therapeutic target in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2022, 55, 1359-1359.	1.9	1
4	Fast-track rescue weight reduction therapy to achieve rapid technical operability for emergency bariatric surgery in patients with life-threatening inoperable severe obesity â€“ A proof of concept study. Clinical Nutrition ESPEN, 2022, 50, 238-246.	0.5	2
5	Diagnostic utility of low hemoglobin density to detect iron deficiency in patients with inflammatory bowel disease. Annals of Gastroenterology, 2021, 34, 521-527.	0.4	2
6	Zinc Protoporphyrin Is a Reliable Marker of Functional Iron Deficiency in Patients with Inflammatory Bowel Disease. Diagnostics, 2021, 11, 366.	1.3	5
7	Letter to the editor: in response to: Richard F Pollock & Patrick Biggar. Indirect methods of comparison of the safety of ferric derisomaltose, iron sucrose and ferric carboxymaltose in the treatment of iron deficiency anemia. Expert Review of Hematology, 2021, , 1-2.	1.0	0
8	Flipside of the Coin: Iron Deficiency and Colorectal Cancer. Frontiers in Immunology, 2021, 12, 635899.	2.2	33
9	Chronic intestinal failure and short bowel syndrome in Crohnâ€™s disease. World Journal of Gastroenterology, 2021, 27, 3440-3465.	1.4	18
10	Osteopontin Levels in Human Milk Are Related to Maternal Nutrition and Infant Health and Growth. Nutrients, 2021, 13, 2670.	1.7	13
11	Wirksamkeit, Sicherheit und Kosten-EffektivitÃt vom intragastrischen Magenballon im Vergleich zu einem multidisziplinÃren Gewichtsreduktionsprogramm (OPTIFAST) - eine Propensity-Score-gematchte Analyse. Zeitschrift Fur Gastroenterologie, 2021, 59, .	0.2	0
12	Hat Biotin-Mangel Einfluss auf die CED-Pathogenese? VorlÃufige Ergebnisse einer Querschnittsstudie. , 2021, 59, .		0
13	Inflammation, but Not the Underlying Disease or Its Location, Predicts Oral Iron Absorption Capacity in Patients With Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2020, 14, 316-322.	0.6	13
14	A Pooled Analysis of Serum Phosphate Measurements and Potential Hypophosphataemia Events in 45 Interventional Trials with Ferric Carboxymaltose. Journal of Clinical Medicine, 2020, 9, 3587.	1.0	16
15	A Multicentre, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Tolerability of the S1P Receptor Agonist KRP203 in Patients with Moderately Active Refractory Ulcerative Colitis. Inflammatory Intestinal Diseases, 2020, 5, 180-190.	0.8	26
16	Inflammation-Induced Mucosal KYNU Expression Identifies Human Ileal Crohnâ€™s Disease. Journal of Clinical Medicine, 2020, 9, 1360.	1.0	13
17	Moderate endurance and muscle training is beneficial and safe in patients with quiescent or mildly active Crohnâ€™s disease. United European Gastroenterology Journal, 2020, 8, 804-813.	1.6	17
18	Measuring Vitamin D Status in Chronic Inflammatory Disorders: How does Chronic Inflammation Affect the Reliability of Vitamin D Metabolites in Patients with IBD?. Journal of Clinical Medicine, 2020, 9, 547.	1.0	12

#	Article	IF	Citations
19	Orale Eisensubstitution (therapie?) bei CED - weniger ist meist mehr?. Zeitschrift Fur Gastroenterologie, 2020, 58, .	0.2	1
20	Art und DurchfÃ¼hrung von PankreasfunktionsprÃ¼fungen. , 2020, , 153-172.		0
21	Percutaneous Endoscopic Gastrostomy (PEG). , 2020, , 208-216.		0
22	P425 Development of an enzyme-linked immunosorbent assay for therapeutic drug monitoring of ustekinumab. Journal of Crohn's and Colitis, 2019, 13, S322-S322.	0.6	0
23	P168 Adjusting serum ferritin concentrations to remove the effects of acute-phase response in patients with IBD and iron deficiency: is using C-reactive protein sufficient?. Journal of Crohn's and Colitis, 2019, 13, S173-S173.	0.6	0
24	P433 Aetiologies of iron deficiency-related anaemia in German patients with inflammatory bowel disease. Journal of Crohn's and Colitis, 2019, 13, S325-S326.	0.6	0
25	Percutaneous endoscopic gastrostomy (PEG): a practical approach for long term management. BMJ: British Medical Journal, 2019, 364, k5311.	2.4	12
26	Letter: An Economic Evaluation of Iron Isomaltoside 1000 Versus Ferric Carboxymaltose in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia in Denmark. Advances in Therapy, 2019, 36, 1817-1820.	1.3	0
27	A75 COMPARISON OF TWO DIFFERENT ASSESSMENT TECHNIQUES FOR MEASUREMENT OF VEDOLIZUMAB TROUGH LEVELS IN ADULT PATIENTS WITH IBD. Journal of the Canadian Association of Gastroenterology, 2019, 2, 151-152.	0.1	0
28	A84 UPDATED SYSTEMATIC REVIEW WITH NETWORK METAANALYSIS ON COMPARATIVE EFFICACY AND TOLERABILITY OF DIFFERENT INTRAVENOUS IRON PRODUCTS FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN PATIENTS WITH IBD. Journal of the Canadian Association of Gastroenterology, 2019, 2, 167-168.	0.1	0
29	A101 SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS: SAFETY OF DIFFERENT INTRAVENOUS IRON PREPARATIONS FOR THE TREATMENT OF IRON DEFICIENCY ANEMIA IN IBD. Journal of the Canadian Association of Gastroenterology, 2019, 2, 201-202.	0.1	0
30	A92 ANALYTICAL PERFORMANCE OF A SMARTPHONE-BASED PATIENT MONITORING SYSTEM COMPARED TO ELISA FOR THE MEASUREMENT OF FECAL CALPROTECTIN IN IBD PATIENTS. Journal of the Canadian Association of Gastroenterology, 2019, 2, 183-184.	0.1	0
31	Is Early Reimplantation of the Duodenalâ€“Jejunal Bypass Liner Viable?. Obesity Surgery, 2019, 29, 1690-1693.	1.1	5
32	P701 The comparative safety of different intravenous iron preparations in inflammatory bowel disease: a systematic review and network meta-analysis. Journal of Crohn's and Colitis, 2019, 13, S471-S472.	0.6	2
33	P719 Update of a network meta-analysis of efficacy and safety of different intravenous iron compounds in patients with IBD and anaemia. Journal of Crohn's and Colitis, 2019, 13, S481-S481.	0.6	0
34	A83 AN ENZYME-LINKED IMMUNOSORBENT ASSAY FOR THERAPEUTIC DRUG MONITORING OF GOLIMUMAB. Journal of the Canadian Association of Gastroenterology, 2019, 2, 166-166.	0.1	0
35	An update on the evaluation and management of iron deficiency anemia in inflammatory bowel disease. Expert Review of Gastroenterology and Hepatology, 2019, 13, 95-97.	1.4	5
36	Serum Hepcidin Levels Predict Intestinal Iron Absorption in Patients with Inflammatory Bowel Disease. Clinical Laboratory, 2019, 65, .	0.2	7

#	Article	IF	Citations
37	Safety and Efficacy of Ferric Carboxymaltose in the Treatment of Iron Deficiency Anaemia in Patients with Inflammatory Bowel Disease, in Routine Daily Practice. Journal of Crohn's and Colitis, 2018, 12, 826-834.	0.6	10
38	A prospective cohort study to assess the relevance of vedolizumab drug level monitoring in IBD patients. Scandinavian Journal of Gastroenterology, 2018, 53, 670-676.	0.6	28
39	P717 Comparison of two different techniques to assess vedolizumab trough levels in adult patients with IBD. Journal of Crohn's and Colitis, 2018, 12, S474-S474.	0.6	1
40	P553 Development of an enzyme-linked immunosorbent assay for therapeutic drug monitoring of golimumab. Journal of Crohn's and Colitis, 2018, 12, S386-S386.	0.6	0
41	P771 Diagnostic performance of low haemoglobin density (LHD%) for detecting iron deficiency in patients with inflammatory bowel disease. Journal of Crohn's and Colitis, 2018, 12, S500-S501.	0.6	0
42	Safety and efficacy of intravenous iron isomaltoside for correction of anaemia in patients with inflammatory bowel disease in everyday clinical practice. Scandinavian Journal of Gastroenterology, 2018, 53, 1059-1065.	0.6	16
43	Design of the Weight-loss Endoscopy Trial (WET): a multi-center, randomized, controlled trial comparing weight loss in endoscopically implanted duodenal-jejunal bypass liners vs. intragastric balloons vs. a sham procedure. BMC Gastroenterology, 2018, 18, 118.	0.8	5
44	Oral versus intravenous iron therapy in patients with inflammatory bowel disease and iron deficiency with and without anemia in Germany – a real-world evidence analysis. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 93-103.	0.7	16
45	Limitations of Serum Ferritin in Diagnosing Iron Deficiency in Inflammatory Conditions. International Journal of Chronic Diseases, 2018, 2018, 1-11.	1.9	134
46	P616 Utility of zinc protoporphyrin/haem ratio as a marker of iron deficiency with or without anaemia in patients with inflammatory bowel disease. Journal of Crohn's and Colitis, 2018, 12, S421-S421.	0.6	0
47	Sa1800 - Diagnostic Performance of Low Haemoglobin Density (LHD%) for Detecting Iron Deficiency in Patients with Inflammatory Bowel Disease. Gastroenterology, 2018, 154, S-400.	0.6	1
48	Tu1269 - 15-D-PGJ2 in the Regulation of Iron Homeostasis. Gastroenterology, 2018, 154, S-920.	0.6	0
49	30. ErnÃhrungstherapie bei Morbus Crohn und Colitis ulcerosa. , 2018, , 493-512.		0
50	Editorial: which iron preparation for patients with <scp>IBD</scp>? Authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2017, 46, 195-196.	1.9	3
51	Systematic review with network metaâ€analysis: comparative efficacy and tolerability of different intravenous iron formulations for the treatment of iron deficiency anaemia in patients with inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2017, 45, 1303-1318.	1.9	87
52	Letter: the importance of dosing and baseline haemoglobin when establishing the relative efficacy of intravenous iron therapiesâ€"authors' reply. Alimentary Pharmacology and Therapeutics, 2017, 46, 705-706.	1.9	4
53	Management of inflammatory bowel disease-related anemia and iron deficiency with specific reference to the role of intravenous iron in current practice. Expert Opinion on Pharmacotherapy, 2017, 18, 1721-1737.	0.9	25
54	Letter: inconsistency in reporting of hypophosphataemia after intravenous ironâ€"authorsâ€™ reply. Alimentary Pharmacology and Therapeutics, 2017, 46, 643-644.	1.9	0

#	Article	IF	Citations
55	Improvement in Glucose Metabolism after Bariatric Surgery: Comparison of Laparoscopic Roux-En-Y Gastric Bypass and Duodenojejunal Bypass. Gastroenterology, 2017, 152, S635-S636.	0.6	0
56	Is Re-Implantation of the Duodenal-Jejunal Bypass Liner Viable?. Gastroenterology, 2017, 152, S135.	0.6	0
57	A Prospective Cohort Study to Assess the Relevance of Vedolizumab Drug Level Monitoring in IBD Patients. Gastroenterology, 2017, 152, S753.	0.6	0
58	Current evaluation and management of anemia in patients with inflammatory bowel disease. Expert Review of Gastroenterology and Hepatology, 2017, 11, 19-32.	1.4	35
59	Improvement of impaired diastolic left ventricular function after diet-induced weight reduction in severe obesity. Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2017, Volume 10, 19-25.	1.1	27
60	Anwendbarkeitsstudie fÃ¼r einen Smartphone-basierten Calprotectin-Test zur Eigenanwendung fÃ¼r CED-Patienten. , 2017, 55, .		0
61	Analytische Performance eines neuen iPhone-basierten Calprotectin-Testes. Zeitschrift Fur Gastroenterologie, 2017, 55, .	0.2	0
62	Anemia and iron deficiency in gastrointestinal and liver conditions. World Journal of Gastroenterology, 2016, 22, 7908.	1.4	103
63	Impact of Severe Obesity and Weight Loss on Systolic Left Ventricular Function and Morphology: Assessment by 2-Dimensional Speckle-Tracking Echocardiography. Journal of Obesity, 2016, 2016, 1-6.	1.1	14
64	1073 Analytical Performance of a New iPhone-Based Patient Monitoring System Comparable to ELISA for Measuring Fecal Calprotectin in IBD Patients. Gastroenterology, 2016, 150, S212.	0.6	0
65	Su1774 15-d-PGJ2 - A Possible Regulator of Iron Metabolism. Gastroenterology, 2016, 150, S546.	0.6	0
66	Su1840 The Efficacy of Intravenous Iron Therapy in IBD Patients With Active Disease Is Not Influenced by the Degree of Inflammatory Activity. Gastroenterology, 2016, 150, S567.	0.6	0
67	Mo1786 A Multi-Center, Double-Blind, Placebo Controlled, Parallel Group, Proof of Concept Study to Evaluate the Efficacy, Safety and Tolerability of the S1P Receptor Modulator Krp203 in Subjects With Moderately Active Refractory Ulcerative Colitis. Gastroenterology, 2016, 150, S775-S776.	0.6	0
68	Efficacy and Safety of Intravenous Ferric Carboxymaltose in Geriatric Inpatients at a German Tertiary University Teaching Hospital: A Retrospective Observational Cohort Study of Clinical Practice. Anemia, 2015, 2015, 1-8.	0.5	12
69	Clinical Significance of C-Reactive Protein Levels in Predicting Responsiveness to Iron Therapy in Patients with Inflammatory Bowel Disease and Iron Deficiency Anemia. Digestive Diseases and Sciences, 2015, 60, 1375-1381.	1.1	28
70	European Consensus on the Diagnosis and Management of Iron Deficiency and Anaemia in Inflammatory Bowel Diseases. Journal of Crohn's and Colitis, 2015, 9, 211-222.	0.6	425
71	Structural modification of resveratrol leads to increased anti-tumor activity, but causes profound changes in the mode of action. Toxicology and Applied Pharmacology, 2015, 287, 67-76.	1.3	27
72	Anaemia in the Elderly IBD Patient. Current Treatment Options in Gastroenterology, 2015, 13, 308-318.	0.3	6

#	Article	IF	Citations
73	Primary Manifestation of Inflammatory Bowel Disease Following Subcutaneous Autovaccination. Journal of Crohn's and Colitis, 2015, 9, 802-805.	0.6	0
74	Mo1742 New Insights in Iron Homeostasis and Inflammatory Diseases: Oncostatin M As a New Player. Gastroenterology, 2015, 148, S-699-S-700.	0.6	0
75	Su1191 Serum Hepcidin Levels Predict Intestinal Iron Absorption in IBD Patients. Gastroenterology, 2015, 148, S-432.	0.6	0
76	Tu1466 Improvement in Glucose Metabolism After Bariatric Surgery: Comparison of Laparoscopic Roux-en-Y Gastric Bypass and Duodenojejunal Bypass Liner. Gastroenterology, 2015, 148, S-900.	0.6	1
77	EntzÃ¼ndliche Erkrankungen des DÃ¼nn- und Dickdarms. , 2015, , 221-286.		0
78	Coeliac Disease - New Pathophysiological Findings and Their Implications for Therapy. Viszeralmedizin, 2014, 30, 156-165.	0.0	9
79	Gastroenteric tube feeding: Techniques, problems and solutions. World Journal of Gastroenterology, 2014, 20, 8505.	1.4	289
80	An Etiologic Profile of Anemia in 405 Geriatric Patients. Anemia, 2014, 2014, 1-7.	0.5	29
81	P314 The type of iron deficiency anaemia, but not the underlying disease, predicts intestinal iron absorption in IBD patients. Journal of Crohn's and Colitis, 2014, 8, S195-S196.	0.6	1
82	P139 Serum hepcidin levels predict intestinal iron absorption in IBD patients. Journal of Crohn's and Colitis, 2014, 8, S120.	0.6	4
83	Review article: the nutritional and pharmacological consequences of obesity surgery. Alimentary Pharmacology and Therapeutics, 2014, 40, 582-609.	1.9	205
84	Resveratrol-induced potentiation of the antitumor effects of oxaliplatin is accompanied by an altered cytokine profile of human monocyte-derived macrophages. Apoptosis: an International Journal on Programmed Cell Death, 2014, 19, 1136-1147.	2.2	21
85	Mo1255 Diagnostic Accuracy of Zinc Protoporphyrin/Heme Ratio for Screening of Iron Deficiency Anaemia in Patients With Inflammatory Bowel Disease. Gastroenterology, 2014, 146, S-599.	0.6	0
86	Mo1771 Adiponectin Antagonises Leptin-Induced Hepcidin Expression in Human Liver Cells: New Insights Into Obesity-Associated Iron Deficiency. Gastroenterology, 2014, 146, S-656.	0.6	0
87	Mo1256 Serum Hepcidin Levels Predict Intestinal Iron Absorption in IBD Patients. Gastroenterology, 2014, 146, S-599.	0.6	0
88	Mo1789 Sulforaphane Inhibits Expression of the Central Iron Regulator Hepcidin STAT3-Independently in an Inflammatory Cell Model. Gastroenterology, 2014, 146, S-660.	0.6	0
89	Current practice in the diagnosis and management of IBD-associated anaemia and iron deficiency in Germany: The German AnaemIBD Study. Journal of Crohn's and Colitis, 2014, 8, 1308-1314.	0.6	42
90	Inadequate Nutrient Intake in Patients with Celiac Disease: Results from a German Dietary Survey. Digestion, 2013, 87, 240-246.	1.2	104

#	Article	IF	Citations
91	Second European evidence-based consensus on the diagnosis and management of ulcerative colitis Part 3: Special situations. Journal of Crohn's and Colitis, 2013, 7, 1-33.	0.6	422
92	Ferric Carboxymaltose Prevents Recurrence of Anemia in Patients With Inflammatory Bowel Disease. Clinical Gastroenterology and Hepatology, 2013, 11, 269-277.	2.4	91
93	Su1303 Long-Term Effects of an Interdisciplinary 52-Week Weight Loss Program on Adipokines and Nonalcoholic Fatty Liver Disease in Obese Patients â€“ A Prospective Evaluation. Gastroenterology, 2013, 144, S-453.	0.6	0
94	Anaemia management in patients with inflammatory bowel disease. European Journal of Gastroenterology and Hepatology, 2013, 25, 1456-1463.	0.8	52
95	Iron Deficiency Generates Secondary Thrombocytosis and Platelet Activation in IBD. Inflammatory Bowel Diseases, 2013, 19, 1609-1616.	0.9	56
96	Management of iron deficiency anemia in inflammatory bowel disease - a practical approach. Annals of Gastroenterology, 2013, 26, 104-113.	0.4	69
97	Selective Glucocorticoid Receptor Agonists for the Treatment of Inflammatory Bowel Disease: Studies in Mice with Acute Trinitrobenzene Sulfonic Acid Colitis. Journal of Pharmacology and Experimental Therapeutics, 2012, 341, 68-80.	1.3	38
98	Sa1346 Evidence of Low Micronutrient Intake in Patients With Celiac Disease. Results From a German Dietary Survey. Gastroenterology, 2012, 142, S-278.	0.6	0
99	Future good scientific publishing practice will necessitate wider data transparency. Current Medical Research and Opinion, 2012, 28, 1881-1882.	0.9	1
100	A Glycerin Hydrogelâ€Based Wound Dressing Prevents Peristomal Infections After Percutaneous Endoscopic Gastrostomy (PEG). Nutrition in Clinical Practice, 2012, 27, 422-425.	1.1	21
101	Clinical case reports raise doubts about the therapeutic equivalence of an iron sucrose similar preparation compared with iron sucrose originator. Current Medical Research and Opinion, 2012, 28, 241-243.	0.9	48
102	1157 Modified Release Phosphatidylcholine LT-02 in Active Ulcerative Colitis - a Randomized, Placebo-Controlled Multicentre Study. Gastroenterology, 2012, 142, S-211.	0.6	2
103	Selective Non-Steroidal Glucocorticoid Receptor Agonists Attenuate Inflammation but Do Not Impair Intestinal Epithelial Cell Restitution In Vitro. PLoS ONE, 2012, 7, e29756.	1.1	21
104	Phytochemicals Resveratrol and Sulforaphane as Potential Agents for Enhancing the Anti-Tumor Activities of Conventional Cancer Therapies. Current Pharmaceutical Biotechnology, 2012, 13, 137-146.	0.9	32
105	Editorial: Pharmazie in unserer Zeit 2/2012. Pharmazie in Unserer Zeit, 2012, 41, 103-103.	0.0	0
106	FERGIcor, a Randomized Controlled Trial on Ferric Carboxymaltose for Iron Deficiency Anemia in Inflammatory Bowel Disease. Gastroenterology, 2011, 141, 846-853.e2.	0.6	304
107	Evidence of Low Micronutrient Intake in Patients With Inflammatory Bowel Disease. Gastroenterology, 2011, 140, S-437.	0.6	1
108	Iron Replacement Therapy for Secondary Thrombocytosis in Inflammatory Bowel Disease: Results of a Randomized Controlled Study â€“ The ThromboVIT Trial. Gastroenterology, 2011, 140, S-265-S-266.	0.6	1

#	Article	IF	Citations
109	Impaired Intestinal Iron Absorption in Inflammatory Bowel Disease Correlates With Disease Activity and Markers of Inflammation but is Independent of Disease Location. Gastroenterology, 2011, 140, S-5.	0.6	4
110	Interferon-Î³ modulates intestinal epithelial cell function in-vitro through a TGFÎ²-dependent mechanism. Regulatory Peptides, 2011, 168, 27-31.	1.9	5
111	Sulforaphane potentiates oxaliplatin-induced cell growth inhibition in colorectal cancer cells via induction of different modes of cell death. Cancer Chemotherapy and Pharmacology, 2011, 67, 1167-1178.	1.1	49
112	Resorptionstests. , 2011, , 89-102.		0
113	Significant Differences Between Crohnâ€™s Disease and Ulcerative Colitis Regarding the Impact of Body Mass Index and Initial Disease Activity on Responsiveness to Azathioprine: Results from a European Multicenter Study in 1,176 Patients. Digestive Diseases and Sciences, 2010, 55, 1066-1078.	1.1	37
114	Isothiocyanate sulforaphane inhibits protooncogenic ornithine decarboxylase activity in colorectal cancer cells via induction of the TGFâ€Î²/Smad signaling pathway. Molecular Nutrition and Food Research, 2010, 54, 1486-1496.	1.5	12
115	T1282 Comparison of Two Commercially Available Serologic Kits for the Detection of Fecal Calprotecin. Gastroenterology, 2010, 138, S-528.	0.6	2
116	T1238 Controlled, Open, Randomized Multicenter Trial Comparing the Effects of Treatment on Quality of Life, Safety and Efficacy of Budesonide and Mesalazine Enemes in Active Left-Sided Ulcerative Colitis. Gastroenterology, 2010, 138, S-518.	0.6	1
117	M1753 Characterization of a Plant-Derived Selective Glucocorticoid Receptor Agonist (SEGRA) for the Treatment of Inflammatory Bowel Disease. Gastroenterology, 2010, 138, S-412.	0.6	1
118	Diagnosis and management of iron deficiency anemia in patients with IBD. Nature Reviews Gastroenterology and Hepatology, 2010, 7, 599-610.	8.2	233
119	222 Isothiocyanate Sulforaphane Inhibits Protooncogenic Ornithine Decarboxylase Activity in Colorectal Cancer Cells via Induction of the TGFÎ²/SMAD Signalling Pathway. Gastroenterology, 2010, 138, S-42.	0.6	0
120	657 Comparative Evaluation of Fecal Calprotectin and S100A12 as Non-Invasive Markers in Predicting Microbiological Diagnosis for Acute Bacterial Diarrhea: Prospective Multicenter Study. Gastroenterology, 2010, 138, S-88.	0.6	0
121	M1806 TNF-Alpha Activates CREB and Induces COX-2 Expression by SRC-Kinases, EGFR and p38 MAPK. Gastroenterology, 2010, 138, S-423.	0.6	0
122	Combined treatment of Caco-2 cells with butyrate and mesalazine inhibits cell proliferation and reduces Survivin protein level. Cancer Letters, 2009, 273, 98-106.	3.2	9
123	187 Comparative Evaluation of a New Semi-Quantitative, Rapid, Office-Based Strip Test with An ELISA-Based Assay for Measuring Fecal Calprotectin to Assess Intestinal Inflammation: Prospective Multicenter Clinical Study. Gastroenterology, 2009, 136, A-34-A-35.	0.6	0
124	427 A 12-Month Interdisciplinary Lifestyle Intervention Improves Risk Factors for Nonalcoholic Fatty Liver Disease in Morbidly Obese Patients â€“ Comparison of Two Noninvasive Scores. Gastroenterology, 2009, 136, A-73.	0.6	1
125	695 Sulforaphane Sensitizes Colorectal Cancer Cells to Oxaliplatin Induced Cell Growth Inhibition: Key Role of p38 MAPK. Gastroenterology, 2009, 136, A-109.	0.6	1
126	696 Resveratrol Sensitizes Colorectal Cancer Cells to Oxaliplatin-Induced Cell Death via Intracellular Polyamine Depletion. Gastroenterology, 2009, 136, A-109.	0.6	0

#	Article	IF	Citations
127	M1191 Impact of Physical Activity On Course of Disease and Quality of Life in Patients with Crohn's Disease. Results from a Prospective Observational Randomized Study. Gastroenterology, 2009, 136, A-369.	0.6	1
128	S1274 Ursolic Acid Inhibits Pro-Angiogenic Factors in Colorectal Cancer Cells Independently of PPARÎ³. Gastroenterology, 2009, 136, A-227.	0.6	0
129	M1092 Prospective Evaluation of Fecal Congranulin a in IBD Based On a New Immuno Assay. Gastroenterology, 2009, 136, A-348.	0.6	0
130	W1963 Molecular Mechanisms of SFN in the Chemoprevention of Colorectal Cancer: Crosstalk Between TGF-Î² and the Protooncogenes COX-2 and ODC. Gastroenterology, 2009, 136, A-762.	0.6	0
131	S1721 The Selective Glucocorticoid Receptor Agonist CpdA Offers Anti-Inflammatory Action Without Affecting TGF-Î² Mediated Intestinal Epithelial Wound Healing. Gastroenterology, 2009, 136, A-257.	0.6	0
132	T1118 New Glycogel Wound Dressing Reduces Wound Infection and Improves Wound Care of Peristomal PEG Sites. Gastroenterology, 2009, 136, A-503.	0.6	0
133	W1613 TNF-Alpha Induced COX-2 Expression By Is Mediated By SRC-Kinases, EGFR and p38 MAPK. Gastroenterology, 2009, 136, A-702.	0.6	0
134	The dietary histone deacetylase inhibitor sulforaphane induces human Î²â€defensinâ€2 in intestinal epithelial cells. Immunology, 2008, 125, 241-251.	2.0	64
135	149 Resveratrol Sensitizes Colorectal Cancer Cells to Oxaliplatin-Induced Cell Death - Possible Key Role of Inhibitor of Apoptosis Proteins. Gastroenterology, 2008, 134, A-26.	0.6	0
136	639 Comparative Evaluation of Fecal Calprotectin, Lactoferrin and Occult Blood Test in Predicting Microbiological Diagnosis for Acute Bacterial Diarrhea: Prospective Multicenter Study. Gastroenterology, 2008, 134, A-91.	0.6	0
137	S1118 Prospective Comparative Evaluation of An Office Based Rapid Immunological Test with a Guaiac Based Fecal Occult Blood Test for Colorectal Cancer Screening in General Population with Average-Risk. Gastroenterology, 2008, 134, A-181-A-182.	0.6	1
138	New introducer PEG gastropexy does not require prophylactic antibiotics: multicenter prospective randomized double-blind placebo-controlled study. Gastrointestinal Endoscopy, 2008, 67, 620-628.	0.5	58
139	Prospective Multicenter Long Term Follow Up Results of New Introducer Percutaneous Endoscopic Gastrostomy Method with Gastropexy in 89 Patients. Gastrointestinal Endoscopy, 2008, 67, AB260.	0.5	0
140	New Glycogel Wound Dressing Modality for Peristomal PEG Dressing: A Simple, Convenient, Economical and Better Option. Gastrointestinal Endoscopy, 2008, 67, AB261-AB262.	0.5	1
141	W1955 Resveratrol Analogues with Potent Anticarcinogenic Properties. Gastroenterology, 2008, 134, A-741-A-742.	0.6	0
142	S1869 TGFÎ²-Dependent Polyamine Depletion Is Associated with Cell Growth Inhibitory Effects of Isothiocyanate Sulforaphane in Colon Cancer Cells. Gastroenterology, 2008, 134, A-285.	0.6	1
143	Prospective Multicenter Study Evaluating Fecal Calprotectin in Adult Acute Bacterial Diarrhea. American Journal of Medicine, 2008, 121, 1099-1106.	0.6	96
144	W1141 Evaluation of a Novel Fecal Marker- Fecal Tumor Pyruvate Kinase Type M2 (M2-PK) and Its Comparison with Calprotectin in Patients with Inflammatory Bowel Disease: A Prospective Multicenter Study. Gastroenterology, 2008, 134, A-642.	0.6	1

#	Article	IF	Citations
145	S1334h An Interdisciplinary Weight Management Program Improves Both Cardiovascular Risk Factors and Nonalcoholic Fatty Liver Disease in Obese Patients. Gastroenterology, 2008, 134, A-230.	0.6	0
146	M1682 Compound a (CpdA), a Selective Glucocorticoid Receptor Agonist (SEGRA), Positively Affects Wound Healing While Reducing NF-KappaB Activity in Intestinal Epithelial Cells. Gastroenterology, 2008, 134, A-396.	0.6	0
147	PPARÂ is involved in mesalazine-mediated induction of apoptosis and inhibition of cell growth in colon cancer cells. Carcinogenesis, 2008, 29, 1407-1414.	1.3	57
148	Nicht-invasive Diagnostik kolorektaler Tumore â€“ Hat der Guaiac-Test ausgedient? / Non-invasive detection of colorectal cancer â€“ do we still need the guaiac-based fecal occult blood test?. Laboratoriums Medizin, 2008, 32, 158-167.	0.1	2
149	Non-invasive detection of colorectal cancer â€“ do we still need the guaiac-based fecal occult blood test? 1. Laboratoriums Medizin, 2008, 32, -.	0.1	0
150	Predictors of reduced healthâ€related quality of life in adults with coeliac disease. Alimentary Pharmacology and Therapeutics, 2007, 25, 569-578.	1.9	88
151	Predictors of Irritable Bowel-Type Symptoms and Healthcare-Seeking Behavior Among Adults With Celiac Disease. Psychosomatic Medicine, 2007, 69, 370-376.	1.3	24
152	Role of nuclear hormone receptors in butyrate-mediated up-regulation of the antimicrobial peptide cathelicidin in epithelial colorectal cells. Molecular Immunology, 2007, 44, 2107-2114.	1.0	59
153	Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NFÎºB signalling. Molecular Immunology, 2007, 44, 3625-3632.	1.0	112
154	New Introducer PEG-Gastropexy with Or Without Prophylactic Antibiotics: A Prospective Double Blind RCT. Gastrointestinal Endoscopy, 2007, 65, AB276.	0.5	0
155	Multicenter Study Using Air Filled Stomach Balloon As a Valid Option for Morbid Obesity. Gastrointestinal Endoscopy, 2007, 65, AB281.	0.5	2
156	Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases#. Inflammatory Bowel Diseases, 2007, 13, 1545-1553.	0.9	373
157	The TGFÎ²/Smad 3-signaling pathway is involved in butyrate-mediated vitamin D receptor (VDR)-expression. Journal of Cellular Biochemistry, 2007, 102, 1420-1431.	1.2	24
158	Prospective evaluation of faecal neutrophilâ€derived proteins in identifying intestinal inflammation: combination of parameters does not improve diagnostic accuracy of calprotectin. Alimentary Pharmacology and Therapeutics, 2007, 26, 1035-1042.	1.9	92
159	Quantitative Immunochemical Fecal Occult Blood Test for Diagnosing Colorectal Neoplasia. Annals of Internal Medicine, 2007, 147, 522.	2.0	3
160	New Introducer PEG with Gastropexy-An Experience in 52 Patients. Gastrointestinal Endoscopy, 2006, 63, AB165.	0.5	0
161	Combining infliximab with methotrexate for the induction and maintenance of remission in refractory Crohn??s disease: a controlled pilot study. European Journal of Gastroenterology and Hepatology, 2006, 18, 11-16.	0.8	54
162	Health-related quality of life in adult coeliac disease in Germany: results of a national survey. European Journal of Gastroenterology and Hepatology, 2006, 18, 747-754.	0.8	89

#	Article	IF	Citations
163	Comparative evaluation of a new bedside faecal occult blood test in a prospective multicentre study. Alimentary Pharmacology and Therapeutics, 2006, 23, 145-154.	1.9	34
164	Long-Term Effectiveness of Azathioprine in IBD Beyond 4 Years: A European Multicenter Study in 1176 Patients. Digestive Diseases and Sciences, 2006, 51, 1516-1524.	1.1	82
165	PPARÎ³ is a key target of butyrate-induced caspase-3 activation in the colorectal cancer cell line Caco-2. Apoptosis: an International Journal on Programmed Cell Death, 2006, 11, 1801-1811.	2.2	53
166	The German hospital malnutrition study. Clinical Nutrition, 2006, 25, 563-572.	2.3	604
167	The New Low Calcemic Vitamin D Analog 22-Ene-25-Oxa-Vitamin D Prominently Ameliorates T Helper Cell Type 1-Mediated Colitis in Mice. Journal of Pharmacology and Experimental Therapeutics, 2006, 319, 622-631.	1.3	63
168	Resorptionstests. , 2006, , 93-123.		3
169	Resorptionstests. , 2006, , 77-87.		0
170	22-ene-25-oxa-vitamin D: a new vitamin D analogue with profound immunosuppressive capacities. European Journal of Clinical Investigation, 2005, 35, 343-349.	1.7	18
171	DiÃtetische Beratung und Behandlung. , 2005, , 765-782.		0
172	Chronisch entzÃ¼ndliche Darmerkrankungen. , 2005, , 248-287.		0
173	Activation of PPARÎ³ is not involved in butyrate-induced epithelial cell differentiation. Experimental Cell Research, 2005, 310, 196-204.	1.2	13
174	Intravenous Iron Sucrose versus Oral Iron Supplementation for the Treatment of Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease-A Randomized, Controlled, Open-Label, Multicenter Study. American Journal of Gastroenterology, 2005, 100, 2503-2509.	0.2	204
175	Upregulation of 25-hydroxyvitamin D₃-1Î±-hydroxylase by butyrate in Caco-2 cells. World Journal of Gastroenterology, 2005, 11, 7136.	1.4	9
176	Molecular Mechanisms of the Chemopreventive Effects of Resveratrol and Its Analogs in Colorectal Cancer: Key Role of Polyamines?. Journal of Nutrition, 2004, 134, 3219-3222.	1.3	77
177	Enteral Nutrition by Endoscopic Means; II. Complications and Management. Zeitschrift Fur Gastroenterologie, 2004, 42, 1393-1398.	0.2	6
178	Enteral Nutrition by Endoscopic Means; I. Techniques, Indications, Types of Enteral Feed. Zeitschrift Fur Gastroenterologie, 2004, 42, 1385-1392.	0.2	12
179	A Study for the Evaluation of Safety and Tolerability of Intravenous High-Dose Iron Sucrose in Patients with Iron Deficiency Anemia due to Gastrointestinal Bleeding. Zeitschrift Fur Gastroenterologie, 2004, 42, 663-667.	0.2	30
180	Combining infliximab and methotrexate in fistulizing Crohn's disease resistant or intolerant to azathioprine. Alimentary Pharmacology and Therapeutics, 2004, 19, 295-301.	1.9	62

#	Article	IF	Citations
181	Modulation of angiogenesis-related protein synthesis by valproic acid. Biochemical and Biophysical Research Communications, 2004, 316, 693-697.	1.0	67
182	p38 MAPK signaling pathway is involved in butyrate-induced vitamin D receptor expression. Biochemical and Biophysical Research Communications, 2004, 324, 1220-1226.	1.0	28
183	Effect of an omega-3 fatty acid containing lipid emulsion alone and in combination with 5-fluorouracil (5-FU) on growth of the colon cancer cell line Caco-2. European Journal of Nutrition, 2003, 42, 324-331.	1.8	71
184	Regulation of mastoparan-induced increase of paracellular permeability in T84 cells by RhoA and basolateral potassium channels. Biochemical Pharmacology, 2003, 65, 1151-1161.	2.0	3
185	Molecular and catalytic properties of three rat leukotriene C4 synthase homologs. Biochemical and Biophysical Research Communications, 2003, 312, 271-276.	1.0	24
186	Butyrate impairs intestinal tumor cell-induced angiogenesis by inhibiting HIF-1Î± nuclear translocation. Biochemical and Biophysical Research Communications, 2003, 300, 832-838.	1.0	76
187	Low Dose Methotrexate in Inflammatory Bowel Disease: Current Status and Future Directions. American Journal of Gastroenterology, 2003, 98, 530-537.	0.2	66
188	Resveratrol-induced modification of polyamine metabolism is accompanied by induction of c-Fos. Carcinogenesis, 2003, 24, 469-474.	1.3	40
189	Short-Chain Fatty Acids and Colon Cancer Cells: The Vitamin D Receptorâ€"Butyrate Connection. Recent Results in Cancer Research, 2003, 164, 247-257.	1.8	43
190	ErnÃhrung bei Krankheiten des Gastrointestinaltrakts. , 2003, , 582-626.		5
191	Piceatannol, a Natural Analog of Resveratrol, Inhibits Progression through the S Phase of the Cell Cycle in Colorectal Cancer Cell Lines. Journal of Nutrition, 2002, 132, 298-302.	1.3	119
192	ZK 156718, a Low Calcemic, Antiproliferative, and Prodifferentiating Vitamin D Analog. Biochemical and Biophysical Research Communications, 2002, 290, 504-509.	1.0	23
193	Resveratrol Enhances the Differentiation Induced by Butyrate in Caco-2 Colon Cancer Cells. Journal of Nutrition, 2002, 132, 2082-2086.	1.3	30
194	Anti-inflammatory drugs modulate C1q secretion in human peritoneal macrophages in vitro. Biochemical Pharmacology, 2002, 64, 457-462.	2.0	6
195	Insufficiently charged isosteric analogue of spermine: interaction with polyamine uptake, and effect on Caco-2 cell growth. Biochemical Pharmacology, 2002, 64, 649-655.	2.0	11
196	Effects of deoxycholate on human colon cancer cells: apoptosis or proliferation. European Journal of Clinical Investigation, 2002, 32, 29-34.	1.7	79
197	Regulation of Î± 1-proteinase inhibitor release by proinflammatory cytokines in human intestinal epithelial cells. Clinical and Experimental Immunology, 2002, 128, 279-284.	1.1	19
198	A randomized prospective trial of immediate vs. next-day feeding after percutaneous endoscopic gastrostomy in intensive care patients. Intensive Care Medicine, 2002, 28, 1656-1660.	3.9	54

#	Article	IF	Citations
199	Resorptionstests. , 2002, , 91-101.		0
200	Butyrate-Induced Differentiation of Caco-2 Cells Occurs Independently from p27. Biochemical and Biophysical Research Communications, 2001, 281, 295-299.	1.0	22
201	1,25-Dihydroxycholecalciferol Enhances Butyrate-Induced p21Waf1/Cip1 Expression. Biochemical and Biophysical Research Communications, 2001, 283, 80-85.	1.0	24
202	Butyrate-Induced Differentiation of Caco-2 Cells Is Mediated by Vitamin D Receptor. Biochemical and Biophysical Research Communications, 2001, 288, 690-696.	1.0	50
203	Deoxycholic acid stimulates migration in colon cancer cells. European Journal of Gastroenterology and Hepatology, 2001, 13, 945-949.	0.8	39
204	Tributyrin, a Stable and Rapidly Absorbed Prodrug of Butyric Acid, Enhances Antiproliferative Effects of Dihydroxycholecalciferol in Human Colon Cancer Cells. Journal of Nutrition, 2001, 131, 1839-1843.	1.3	50
205	Downregulation of the Cyclin D1/Cdk4 Complex Occurs during Resveratrol-Induced Cell Cycle Arrest in Colon Cancer Cell Lines. Journal of Nutrition, 2001, 131, 2197-2203.	1.3	187
206	Flux of amino acids and energy substrates across the leg in weight-stable HIV-infected patients with acute opportunistic infections: indication of a slow protein wasting process. Journal of Molecular Medicine, 2001, 79, 671-678.	1.7	6
207	Nonsteroidal anti-inflammatory drugs stimulate spermidine/spermine acetyltransferase and deplete polyamine content in colon cancer cells. European Journal of Clinical Investigation, 2001, 31, 887-893.	1.7	44
208	Butyrate and the cytokine-induced Î±1-proteinase inhibitor release in intestinal epithelial cells. European Journal of Clinical Investigation, 2001, 31, 1060-1063.	1.7	7
209	Hydroxylamine-containing inhibitors of polyamine biosynthesis and impairment of colon cancer cell growth11Abbreviations: AMA, S-(5â€²-deoxy-5â€²-adenosyl)-methylthioethyl-hydroxylamine; APA, 1-aminooxy-3-aminopropane; DFMO, alpha-difluoromethylornithine; DMEM, Dulbeccoâ€™s modified Eagleâ€™s medium; DTT, dithiothreitol; EGF, epidermal growth factor; 5-FU, 5-fluorouracil; LDH, lactate dehydrogenase; MGBG, methyl-bisguanylhydrazone; SAM, S-adenosylmethionine; SAMDC,	2.0	30
210	Permeability characteristics of polyamines across intestinal epithelium using the Caco-2 monolayer system: comparison between transepithelial flux and mitogen-stimulated uptake into epithelial cells. Nutrition, 2001, 17, 462-466.	1.1	15
211	Modulation of epidermal growth factor-induced cell proliferation by an Ï‰-3 fatty-acid-containing lipid emulsion on human pancreatic cancer cell line Mia Paca-2. Nutrition, 2001, 17, 474-475.	1.1	13
212	Folate and chemoprevention of colorectal cancer: is 5-methyl-tetrahydrofolate an active antiproliferative agent in folate-treated colon-cancer cells?. Nutrition, 2001, 17, 652-653.	1.1	33
213	HMG-CoA reductase inhibitor mevastatin enhances the growth inhibitory effect of butyrate in the colorectal carcinoma cell line Caco-2. Carcinogenesis, 2001, 22, 1061-1067.	1.3	106
214	Transepithelial transport of putrescine across monolayers of the human intestinal epithelial cell line, Caco- 2. World Journal of Gastroenterology, 2001, 7, 193.	1.4	14
215	Effect of structural analogues of propionate and butyrate on colon cancer cell growth. International Journal of Colorectal Disease, 2000, 15, 264-270.	1.0	21
216	Rationale for the luminal provision of butyrate in intestinal diseases. European Journal of Nutrition, 2000, 39, 164-171.	1.8	220

#	Article	IF	Citations
217	Short-chain fatty acid (SCFA) uptake into Caco-2 cells by a pH-dependent and carrier mediated transport mechanism. European Journal of Nutrition, 2000, 39, 121-125.	1.8	74
218	Application of the Colon-Simulation Technique for Studying the Effects of Saccharomyces boulardii on Basic Parameters of Porcine Cecal Microbial Metabolism Disturbed by Clindamycin. Digestion, 2000, 61, 193-200.	1.2	29
219	EGF-Stimulated Polyamine Accumulation in the Colon Carcinoma Cell Line, Caco-2. Digestion, 2000, 61, 230-236.	1.2	10
220	Substrate and Inhibitor Specificity of Butyrate Uptake in Apical Membrane Vesicles of the Rat Distal Colon. Digestion, 2000, 62, 152-158.	1.2	23
221	Expression of 5-Lipoxygenase by Human Colorectal Carcinoma Caco-2 Cells during Butyrate-Induced Cell Differentiation. Biochemical and Biophysical Research Communications, 2000, 268, 778-783.	1.0	35
222	PPAR-Î³ Is Selectively Upregulated in Caco-2 Cells by Butyrate. Biochemical and Biophysical Research Communications, 2000, 272, 380-385.	1.0	82
223	Low-dose deoxycholic acid stimulates putrescine uptake in colon cancer cells (Caco-2). Cancer Letters, 2000, 154, 195-200.	3.2	24
224	Analysis of Lowâ€Molecularâ€Weight GTPâ€Binding Proteins in Two Functionally Different Intestinal Epithelial Cell Lines. Annals of the New York Academy of Sciences, 2000, 915, 223-230.	1.8	1
225	Epidermal Growth Factor, Polyamines, and Epithelial Remodeling in Cacoâ€2 Cells. Annals of the New York Academy of Sciences, 2000, 915, 279-281.	1.8	4
226	Superoxide: A Major Factor for Stress Protein Induction in Reoxygenation Injury in the Intestinal Cell Line Caco-2. Digestion, 1999, 60, 238-245.	1.2	23
227	Chemically defined structured lipids: current status and future directions in gastrointestinal diseases. International Journal of Colorectal Disease, 1999, 14, 79-85.	1.0	35
228	Mediation of differentiating effects of Butyrate on the intestinal cell line Caco-2 by transforming growth factor-Î²1. European Journal of Nutrition, 1999, 38, 45-50.	1.8	26
229	Diseases of the small intestine. European Journal of Gastroenterology and Hepatology, 1999, 11, 21-26.	0.8	9
230	Funktionsdiagnostik. , 1999, , 163-180.		3
231	Influence of Epidermal Growth Factor/Transforming Growth Factor Alpha and Polyamines on Caco-2 Cell Proliferation. Annals of the New York Academy of Sciences, 1998, 859, 198-200.	1.8	3
232	HSP27 induction after heat shock and free radical exposure in IEC-6 cells. Gastroenterology, 1998, 114, A409.	0.6	0
233	Polyamine Uptake Across the Basolateral Membrane of the Enterocyte Is Mediated by a High-Affinity Carrier. Digestion, 1998, 59, 60-68.	1.2	13
234	S-adenosylmethionine decarboxylase activity and utilization of exogenous putrescine are enhanced in colon cancer cells stimulated to grow by EGF. Zeitschrift Fur Gastroenterologie, 1998, 36, 947-54.	0.2	14

#	Article	IF	Citations
235	[30] High-performance liquid chromatographic determination of biotin in biological materials after crown ether-catalyzed fluorescence derivatization with panacyl bromide. Methods in Enzymology, 1997, 279, 286-295.	0.4	6
236	Dual role for AlF4(-)-sensitive G proteins in the function of T84 epithelial cells: transport and barrier effects. American Journal of Physiology - Cell Physiology, 1997, 272, C794-C803.	2.1	22
237	New Fecal Tests in the Diagnosis of Exocrine Pancreatic Insufficiency. , 1997, , 277-289.		3
238	Induction of glutathione-S-transferase-pi by short-chain fatty acids in the intestinal cell line caco-2. European Journal of Clinical Investigation, 1996, 26, 84-87.	1.7	26
239	Epidermal Growth Factor Receptor Signaling in Rat Pancreatic Acinar Cells. Pancreas, 1995, 10, 274-280.	0.5	11
240	Characterization of putrescine transport across the intestinal epithelium: study using isolated brush border and basolateral membrane vesicles of the enterocyte. European Journal of Clinical Investigation, 1995, 25, 97-105.	1.7	33
241	Subcellular distribution of small GTP-binding proteins in the intestinal cell line Caco-2. European Journal of Clinical Investigation, 1995, 25, 793-795.	1.7	2
242	Isolation and characterization of apical membrane vesicles of the rat distal colon. Research in Experimental Medicine, 1995, 195, 333-342.	0.7	3
243	High-performance liquid chromatographic determination of nicotinic acid and nicotinamide in biological samples applying post-column derivatization resulting in bathmochrome absorption shifts. Biomedical Applications, 1995, 665, 71-78.	1.7	13
244	EGF Stimulates Polyamine Uptake in Caco-2 Cells. Biochemical and Biophysical Research Communications, 1995, 206, 962-968.	1.0	39
245	Mercaptopropionate inhibits butyrate uptake in isolated apical membrane vesicles of the rat distal colon. Gastroenterology, 1995, 108, 673-679.	0.6	33
246	Rapid Postabsorptive Metabolism of Nicotinic Acid in Rat Small Intestine May Affect Transport by Metabolic Trapping. Journal of Nutrition, 1994, 124, 61-66.	1.3	11
247	Simultaneous preparation of rabbit intestinal brush border and basolateral membrane vesicles. Research in Experimental Medicine, 1994, 194, 305-312.	0.7	3
248	Near-infrared reflectance analysis. European Journal of Gastroenterology and Hepatology, 1994, 6, 889-894.	0.8	41
249	Preparation of basolateral membrane vesicles from rat enterocytes: influence of different gradient media. Physiological Research, 1994, 43, 75-81.	0.4	4
250	Reduced postheparin plasma diamine oxidase activity in patients with chronic renal failure. Zeitschrift Fur Gastroenterologie, 1994, 32, 236-9.	0.2	6
251	Effects of guanine nucleotides on bombesin-stimulated signal transduction in rat pancreatic acinar cells. Research in Experimental Medicine, 1993, 193, 323-335.	0.7	2
252	Fluorometric High-Performance Liquid Chromatography of Free Fatty Acids Using Panacyl Bromide. Journal of Liquid Chromatography and Related Technologies, 1993, 16, 2915-2922.	0.9	9

#	Article	IF	Citations
253	High-performance liquid chromatographic determination of biotin in biological materials after crown ether-catalyzed fluorescence derivatization with panacyl bromide. Analytical Biochemistry, 1992, 200, 89-94.	1.1	21
254	Characteristics of putrescine uptake by human brush border membrane vesicles. Zeitschrift Fur Gastroenterologie, 1992, 30, 841-5.	0.2	3